RJFSA
NRIX icon

Raymond James Financial Services Advisors’s Nurix Therapeutics NRIX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,826
Closed -$1.16M – 3378
2021
Q2 		$1.16M Buy
+43,826
New +$1.29M ﹤0.01% 1853

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Raymond James Financial Services Advisors's NRIX Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Nurix Therapeutics (NRIX) in Q3 2021, closing a stake of 43,826 shares — an estimated $1.16M sold.

Raymond James Financial Services Advisors first reported a position in NRIX in Q2 2021 and held it in 1 quarter. The position peaked at $1.16M in Q2 2021. 113 funds tracked by Wall St. Rank hold NRIX as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Nurix Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 43,826 Nurix Therapeutics shares in Q3 2021, an estimated $1.16M.
  • Raymond James Financial Services Advisors first reported a position in Nurix Therapeutics in Q2 2021 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Nurix Therapeutics position peaked at $1.16M in Q2 2021.
  • 113 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.